GLP-1 microdosing: what it is and how the doses actually compare

What is GLP-1 microdosing?

GLP-1 microdosing is the use of compounded semaglutide or compounded tirzepatide at doses below the standard FDA-approved therapeutic range. The term has become popular in 2024-2026 as more patients use compounded GLP-1 medications and providers experiment with personalized dose-response patterns. It is not a manufacturer-defined or FDA-recognized dosing protocol — it is a clinical practice pattern that has emerged in compounded GLP-1 medicine.

Three clinical reasons patients microdose:

Side-effect sensitivity. Standard FDA-approved starter doses (semaglutide 0.25mg weekly, tirzepatide 2.5mg weekly) produce meaningful nausea, diarrhea, or constipation in approximately 25-40% of patients during titration. Microdosing below the standard starter dose can reduce side-effect intensity for these patients while still producing modest appetite suppression.

Maintenance after weight loss. Patients who reached a goal weight on a higher dose sometimes step down to a microdose to maintain results with less medication exposure (and lower cost).

Minimum effective dose strategies. Some patients respond strongly to lower doses than the trial-defined therapeutic range. Microdosing tests whether a given patient needs the full labeled dose to achieve their goals.

GLP-1 microdose comparison chart

The following chart compares typical microdose ranges to the FDA-approved therapeutic ranges for branded products. Microdosing of compounded GLP-1 medications is not FDA-recognized and lacks large-scale trial validation. The clinical effects of microdoses are extrapolated from the dose-response curves observed in the STEP and SURMOUNT trials of branded products.

Semaglutide microdose details

Compounded semaglutide microdoses typically fall between 0.1mg and 0.25mg per week. Below 0.1mg, the dose is unlikely to produce meaningful clinical effect. Above 0.25mg, the dose enters the standard FDA-approved starter range.

In the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), the FDA-approved 2.4mg weekly maintenance dose of brand-name Wegovy® produced approximately 14.9% mean weight loss over 68 weeks. There is no published trial-scale data on weight loss at 0.1mg-0.25mg. Patient-reported outcomes from clinical practice suggest mild appetite suppression and modest weight reduction at the microdose range, but quantitative comparison against the trial data is not possible.

Practical considerations:

• Microdoses typically produce milder gastrointestinal side effects than standard starter doses, making them tolerable for patients who could not previously titrate up
• Microdoses require the same once-weekly injection schedule as standard doses
• Some patients use microdoses as a "test run" — establishing tolerability at the microdose before titrating up to the standard therapeutic range
• Some patients maintain on microdoses long-term after reaching a goal weight

Tirzepatide microdose details

Compounded tirzepatide microdoses typically fall between 1.25mg and 2.5mg per week. The 2.5mg dose is the standard FDA-approved Zepbound® starter dose used in the SURMOUNT-1 trial. Below 1.25mg, the dose is unlikely to produce meaningful clinical effect.

In the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022), the FDA-approved 15mg weekly maintenance dose of brand-name Zepbound® produced approximately 22.5% mean weight loss over 72 weeks. There is no published trial-scale data on weight loss at 1.25mg. Clinical practice patterns suggest the 1.25mg dose produces some appetite suppression and modest weight reduction, but with much smaller magnitude than the 15mg trial dose.

Most compounded tirzepatide patients do not microdose long-term — the typical dosing pattern in compounded GLP-1 telehealth follows the same 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg titration schedule that the SURMOUNT trials used. Microdosing is more common as either a starter-dose substitute for side-effect-sensitive patients or as a post-maintenance step-down.

What microdose results to actually expect

No large-scale published clinical trials have evaluated microdosed compounded GLP-1 medications. Any predictions about microdose effects are extrapolations from the dose-response curves of FDA-approved branded products in their published trials.

General expectations based on extrapolation (individual results vary substantially):

• Mild appetite suppression: most patients on microdoses report less hunger than baseline, but the effect is typically subtler than at standard starter doses
• Modest weight reduction: weight loss at microdoses is generally less than half of the loss seen at standard maintenance doses in trials, but is non-zero for many patients
• Lower side-effect intensity: gastrointestinal effects, fatigue, and other side effects tend to be milder at microdoses
• Slower onset: meaningful effects may take 4-8 weeks at microdoses vs 2-4 weeks at standard starter doses

Is microdosing safe?

Microdosing of compounded GLP-1 medications under the supervision of a licensed provider is generally considered safe — the safety profile of semaglutide and tirzepatide at low doses is well-characterized through the early titration phases of the FDA-approved branded products. The main safety considerations:

• Microdosing should be done under provider supervision. Self-dosing below the labeled range increases medication-error risk and may delay diagnosis of weight-related conditions that warrant standard therapeutic doses
• Compounded medications are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or manufacturing quality. Compounded versions are not therapeutically equivalent to brand-name FDA-approved products
• Microdoses still produce real pharmacological effects — fasting glucose changes, mild blood pressure shifts, and other systemic responses that should be monitored
• Microdosing is generally not appropriate for patients with type 2 diabetes seeking glucose management — therapeutic dosing has clinical evidence; microdosing does not
• Patients should never adjust their own dose without consulting their prescribing provider

How Cora Health approaches dosing

Cora Health does not prescribe medication. Cora Health connects patients with licensed providers at Wasef Health, PC who evaluate each patient individually and — when clinically appropriate — write a patient-specific prescription. Dose decisions are made by the provider based on the patient's health profile, prior medication tolerance, treatment goals, and side-effect response.

Cora Health's compounded semaglutide and compounded tirzepatide can be prescribed at standard therapeutic doses or at microdoses depending on the provider's clinical judgment. Patients interested in microdosing should mention this preference during the initial assessment so the provider can evaluate whether it is appropriate.

Compounded GLP-1 medications are not FDA-approved and not therapeutically equivalent to brand-name FDA-approved products. Individual results vary substantially.

Sources

All efficacy data references trials of FDA-approved branded products. Compounded versions have not been evaluated at trial scale.

• STEP 1 trial — Wilding et al., New England Journal of Medicine 2021 (FDA-approved Wegovy® 2.4mg, ~14.9% mean weight loss): nejm.org/doi/full/10.1056/NEJMoa2032183
• SURMOUNT-1 trial — Jastreboff et al., New England Journal of Medicine 2022 (FDA-approved Zepbound® 15mg, ~22.5% mean weight loss): nejm.org/doi/full/10.1056/NEJMoa2206038
• FDA — Compounding and the FDA: Questions and Answers: fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• LegitScript — Independent verification of Cora Health certification: legitscript.com/websites/?checker_keywords=trycora.io